GSK provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)
GSK plc (LSE/NYSE: GSK) today provides an update on the CALM-1 and CALM-2 phase III clinical trials
Trial Results • Phase 3
Company profile
GSK
Pipeline26 assets
- ArexvyArexvy / RSV F protein / Recombinant protein, adjuvanted vaccine / Infectious diseasesRSV adults (50-59 years of age at increased risk)Phase III/Registration
- gepotidacinGSK2140944 / Bacterial topoisomerase inhibitor / Small molecule / Infectious diseasesUrogenital gonorrhoeaPhase III/Registration
- bepirovirsenGSK3228836 / HBsAg / Antisense oligonucleotide / Infectious diseasesChronic HBV infectionPhase III
- BexseroBexsero / MenB / Recombinant protein, OMV vaccine / Infectious diseasesMeningitis B (infants US)Phase III/RegistrationUS
- MenABCWY vaccineGSK3536819 / Meningococcal ABCWY / Recombinant protein, OMV, conjugated vaccine / Infectious diseasesMeningococcal diseasePhase III/Registration
- Nucala (mepolizumab)Nucala / IL-5 / Monoclonal antibody / Respiratory/ImmunologyCOPD with eosinophilic phenotypePhase III/Registration
- depemokimabGSK3511294 / IL-5 / Monoclonal antibody / Respiratory/ImmunologyAsthma with type 2 inflammationPhase III/RegistrationChronic rhinosinusitis with nasal polypsPhase III/RegistrationEGPAPhase III
- camlipixantGSK4523199 / P2X3 / Small molecule antagonist / Respiratory/ImmunologyRefractory chronic coughPhase III
- linerixibatGSK2330672 / IBAT / Small molecule / Respiratory/ImmunologyCholestatic pruritus in primary biliary cholangitisPhase III
- Blenrep (belantamab mafodotin)GSK2857916 / Blenrep / BCMA / Antibody-drug conjugate / OncologyRelapsed/refractory multiple myelomaPhase III/Registration
- Jemperli (dostarlimab)Jemperli / PD-1 / Monoclonal antibody / OncologyEndometrial cancerPhase III/RegistrationRectal cancer (dMMR)Phase IINon-small cell lung cancerPhase III
- Zejula (niraparib)Zejula / PARP / Small molecule / OncologyOvarian cancerPhase III/Registration
- belrestotugGSK4428859 / TIGIT / Monoclonal antibody / OncologyNSCLC and other solid tumorsPhase III
- GSK5764227GSK5764227 / B7-H3 / Antibody-drug conjugate / OncologyExtensive-stage small-cell lung cancerPhase IIIAdvanced GI solid tumorsPhase I/II
- cobolimabGSK4069889 / TIM-3 / Monoclonal antibody / OncologyNon-small cell lung cancerPhase II/III
- GSK4532990GSK4532990 / HSD17B13 / RNA interference / Opportunity drivenNASH/MASHPhase II
- GSK4172239GSK4172239 / DNMT1 / Small molecule inhibitor / Opportunity drivenSickle cell diseasePhase I
- GSK3882347GSK3882347 / FimH / Small molecule antagonist / Infectious diseasesUncomplicated UTIPhase I
- GSK3923868GSK3923868 / PI4K beta / Small molecule inhibitor / Infectious diseasesRhinovirus diseasePhase I
- GSK3965193GSK3965193 / PAPD5/PAPD7 / Small molecule inhibitor / Infectious diseasesChronic HBV infectionPhase I
- GSK2556286GSK2556286 / Mtb cholesterol-dependent / Small molecule inhibitor / Infectious diseasesTuberculosisPhase I
- GSK3772701GSK3772701 / P. falciparum whole cell / Small molecule inhibitor / Infectious diseasesMalariaPhase I
- GSK4024484GSK4024484 / P. falciparum whole cell / Small molecule inhibitor / Infectious diseasesMalariaPhase I
- GSK3536867GSK3536867 / Salmonella typhoid + paratyphoid A / Bivalent conjugate vaccine / Infectious diseasesSalmonella (typhoid + paratyphoid A)Phase I
- AGN-151586 / progranulin program (latozinemab)AL001 / Progranulin/sortilin / Monoclonal antibody / Opportunity drivenFrontotemporal dementia with progranulin gene mutationPhase III
Latest news25 items
All newsGSK completes acquisition of Nuvalent, Inc.
GSK plc today announced completion of its acquisition of Nuvalent, Inc. , a Boston-based clinical-stage biopharmaceutical company.
Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer
Results support potential for dostarlimab to eliminate the need for chemotherapy, radiation and surgery in some patients
Trial Results • Phase 2
GSK’s licensor Hansoh Pharma announces positive phase III results for Ris-Rez in China patient population
ARTEMIS-008 met its primary endpoint of overall survival in advanced or relapsed small-cell lung cancer
Trial Results • Phase 3
Roy Jakobs to join GSK Board as Non-Executive Director
Roy Jakobs will join the Board of the Company as a Non-Executive Director from 13 July 2026.
GSK announces commencement of tender offer to acquire Nuvalent, Inc.
GSK plc today announced that Harmony Row Acquisition Co. has commenced a tender offer to purchase all of the shares of Nuvalent, Inc.
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
More than 3 million cases of cUTIs are treated annually in the US with up to a third of patients impacted by resistant infections.
GSK’s momelotinib granted Orphan Drug Designations in the US and EU for VEXAS syndrome
VEXAS syndrome is a rare, life-threatening haemato-inflammatory condition with no approved treatments.
GSK enters agreement to acquire Nuvalent, Inc.
Acquisition expected to be accretive to sales & core operating profit in 2027 & core EPS in 2029 inclusive of synergies and reprioritisation
Bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
Pivotal B-Well data show a significant 19% functional cure in the overall study population and 26% in patients with lower viral activity.
Trial Results • Phase 3
GSK to showcase long-term outcomes and pipeline expansion with latest oncology research at ASCO and EHA
GSK will present new data from its expanding oncology portfolio and pipeline at ASCO and EHA.
Presentation / Abstract • Phase 3ASCO abstract release Fri, May 29, 2026
GSK’s RSV vaccine, Arexvy, receives expanded approval in Japan for adults aged 18–59 at increased risk
First RSV vaccine approved for adults aged 18-59 years at increased risk and for all adults 60 years and older in Japan
GSK enters exclusive collaboration with SBP Group, a market leader in hepatology in China, to accelerate bepirovirsen at launch
Bepirovirsen is a potential first-in-class treatment for chronic hepatitis B, under priority regulatory review in China
GSK presents latest respiratory research to advance patient care at ATS 2026
Patient preference and adherence research highlight potential of long-acting dosing regimens to improve clinical outcomes in severe asthma
Presentation / Abstract • Phase 3
GSK delivers strong Q1 performance and start to 2026
Q1 2026 highlights
Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA
Breakthrough Therapy Designation added to Fast Track Designation, recognising potential for substantial improvement over existing treatments
GSK’s investigational liver therapy, efimosfermin, receives US FDA Breakthrough Therapy and EMA Priority Medicines (PRIME) designations for MASH
Designations recognise potential for efimosfermin to address significant unmet medical need & reflect momentum in GSKs liver health pipeline
TESARO, a GSK subsidiary, provides update on AnaptysBio, Inc. litigation
Delaware Chancery Court has granted the motion to dismiss filed by AnaptysBio, Inc. against TESARO’s claim for anticipatory breach.
Blenrep (belantamab mafodotin) approved in China for treatment of 2L+ relapsed/refractory multiple myeloma
As the only anti-BCMA approved in 2L+ multiple myeloma in China, Blenrep provides a new and needed mechanism of action in therapy.
GSK completes acquisition of 35Pharma Inc.
GSK today announced the completion of its previously announced acquisition of 35Pharma Inc.
GSK presents positive data for B7-H4-targeted ADC in gynaecological cancers
Promising efficacy and safety profile supports start of five pivotal phase III trials in 2026.
Trial Results • Phase 1
Exdensur (depemokimab) approved in China for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP)
Exdensur is the first and only ultra-long-acting biologic in China for CRSwNP
Exdensur (depemokimab) approved in China for the treatment of severe asthma
Exdensur is the first and only ultra-long-acting biologic in China for the treatment of severe asthma with an eosinophilic phenotype.
Bepirovirsen accepted for regulatory review in China as a potential first-in-class functional cure for chronic hepatitis B
Submission supported by statistically significant and clinically meaningful functional cure rates in pivotal Phase III B-Well trials
Bepirovirsen accepted for review by the European Medicines Agency as a potential first-in-class treatment for chronic hepatitis B
Submission supported by statistically significant and clinically meaningful functional cure rates in pivotal PhIII B-Well trials